89. Lymphangioleiomyomatosis
[
30 clinical trials,
28 drugs（DrugBank:
17 drugs),
26 target genes / 126 target pathways ]
Searched query = "Lymphangioleiomyomatosis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03253913 | March 31, 2018 | 11 June 2018 | Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial | Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT) | Lymphangioleiomyomatosis | Drug: Sirolimus;Drug: Resveratrol | University of Cincinnati | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 18 Years | N/A | Female | 25 | Phase 2 | United States |
| 2 | NCT03131999 | January 23, 2018 | 30 September 2019 | LAM Pilot Study With Imatinib Mesylate | LAM Pilot Study With Imatinib Mesylate | Lymphangioleiomyomatosis | Drug: Imatinib Mesylate 400Mg Capsule;Drug: Placebo - Capsule | Medical University of South Carolina | Columbia University | Not recruiting | 18 Years | N/A | All | 18 | Phase 1/Phase 2 | United States |
| 3 | NCT03150914 | January 1, 2018 | 26 August 2019 | Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial | Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial | LAM;Lymphangioleiomyomatosis | Drug: Sirolimus | University of Cincinnati | National Heart, Lung, and Blood Institute (NHLBI);National Center for Advancing Translational Science (NCATS);The LAM Foundation | Recruiting | 18 Years | N/A | Female | 60 | Phase 3 | United States |
| 4 | NCT03062943 | October 2016 | 26 August 2019 | A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) | A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM) | Lymphangioleiomyomatosis | Drug: Nintedanib | IRCCS Multimedica | Recruiting | 18 Years | N/A | Female | 30 | Phase 2 | Italy | |
| 5 | NCT02737202 | April 2016 | 5 February 2018 | Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis | Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis | Pulmonary Lymphangioleiomyomatosis | Drug: saracatinib | Baylor College of Medicine | University of Cincinnati;Brigham and Women's Hospital;Stanford University;Loyola University;University of South Florida;National Institutes of Health (NIH) | Recruiting | 18 Years | 65 Years | Female | 28 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2015-004919-20-IT | 09/03/2016 | 16 August 2016 | A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) | A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) - A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) | Female subjects affected by Llymphangioleiomyomatosis (LAM) MedDRA version: 19.0 Level: PT Classification code 10049459 Term: Lymphangioleiomyomatosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Pharmaceutical Form: Capsule, soft | MULTIMEDICA S.P.A. | Authorised | Female: yes Male: no | 30 | Phase 3 | Italy | |||
| 7 | NCT02484664 | January 2016 | 28 January 2019 | COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC | COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC | Lymphangioleiomyomatosis (LAM) | Drug: Celecoxib | Brigham and Women's Hospital | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 18 Years | 70 Years | Female | 12 | Phase 2 | United States |
| 8 | NCT02432560 | March 2015 | 14 October 2019 | Safety and Durability of Sirolimus for Treatment of LAM | Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS) | Lymphangioleiomyomatosis | Drug: Sirolimus;Drug: Everolimus | University of Cincinnati | Rare Diseases Clinical Research Network;National Institutes of Health (NIH);National Heart, Lung, and Blood Institute (NHLBI);The LAM Foundation | Not recruiting | 18 Years | N/A | Female | 600 | Phase 2 | United States |
| 9 | JPRN-UMIN000016677 | 2015/01/01 | 2 April 2019 | Efficacy and safety of low dose sirolimus in lymphangioleiomyomatosis | lymphangioleiomyomatosis | sirolimus 1mg/day / sirolimus 2mg/day | National Hospital Organization Kinki-chuo Chest Medical Center | Recruiting | Not applicable | Not applicable | Male and Female | 20 | Not selected | Japan | ||
| 10 | NCT02116712 | August 2014 | 12 December 2016 | The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1) | The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1) | Pulmonary Lymphangioleiomyomatosis | Drug: Saracatinib | Tony Eissa | University of Texas;University of Cincinnati | Not recruiting | 18 Years | 65 Years | Both | 9 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02061397 | March 2014 | 25 February 2019 | Safety of Simvastatin in LAM and TSC | The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC) | Lymphangioleiomyomatosis;Tuberous Sclerosis Complex | Drug: Simvastatin | University of Pennsylvania | The LAM Foundation | Not recruiting | 18 Years | N/A | Female | 10 | Phase 1/Phase 2 | United States |
| 12 | NCT01799538 | June 10, 2013 | 11 November 2019 | Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | 13-H-0051 Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Subjects With Lymphangioleiomyomatosis | Lymphangioleiomyomatosis | Drug: albuterol inhaler;Drug: albuterol nebulizer;Procedure: PFT | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 18 Years | 80 Years | Female | 100 | Phase 1 | United States | |
| 13 | JPRN-JMA-IIA00096 | 05/09/2012 | 2 April 2019 | multicenter lymphangioleiomyomatosis sirolimus trial for safety | multicenter lymphangioleiomyomatosis sirolimus trial for safety | lymphangioleiomyomatosis | Intervention type:DRUG. Intervention1:Srolimus, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:LAM patients will be medicated with 2mg of sirolimus every day for 2 years and modified dosage between 1mg and 3mg QD depend on the plasma concentration monitoring.. | Koh Nakata, MD, PhD | Yoshikazu Inoue Kuniaki Seyama Ryushi Tazawa Toshinori Takada | Not Recruiting | >=18 YEARS | No Limit | Female | 65 | Phase 2 | Japan |
| 14 | NCT01687179 | September 2012 | 22 August 2016 | Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis | Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus | Lymphangioleiomyomatosis | Drug: sirolimus and hydroxychloroquine | Brigham and Women's Hospital | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 18 Years | 85 Years | Female | 14 | Phase 1 | United States |
| 15 | JPRN-UMIN000007387 | 2012/03/31 | 2 April 2019 | Clinical trials for long-term administration of sirolimus for lymphangioleiomyomatosis | lymphangioleiomyomatosis | sirolimus | Kobe University Graduate School of Medicine | Recruiting | Not applicable | Not applicable | Female | 1 | Not applicable | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT01552434 | March 16, 2012 | 30 September 2019 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications | Advanced Malignant Neoplasm;Castleman Disease;Digestive System Carcinoma;Erdheim-Chester Disease;Lip and Oral Cavity Carcinoma;Lymphangioleiomyomatosis;Malignant Endocrine Neoplasm;Malignant Female Reproductive System Neoplasm;Malignant Male Reproductive System Neoplasm;Malignant Neoplasm;Malignant Respiratory Tract Neoplasm;Malignant Thoracic Neoplasm;Malignant Urinary System Neoplasm;Mesothelial Neoplasm;Metastatic Malignant Neoplasm;Metastatic Urothelial Carcinoma;Neurofibromatosis Type 2;Recurrent Adult Soft Tissue Sarcoma;Recurrent Breast Carcinoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Digestive System Carcinoma;Recurrent Female Reproductive System Carcinoma;Recurrent Male Reproductive System Carcinoma;Recurrent Malignant Neoplasm;Recurrent Pharyngeal Carcinoma;Recurrent Thyroid Gland Carcinoma;Refractory Malignant Neoplasm;Soft Tissue Neoplasm;Stage III Breast Cancer AJCC v7;Stage III Pharyngeal Cancer;Stage IIIA Breast Cancer AJCC v7;Stage IIIB Breast Cancer AJCC v7;Stage IIIC Breast Cancer AJCC v7;Stage IV Breast Cancer AJCC v6 and v7;Stage IV Pharyngeal Cancer;Stage IVA Pharyngeal Cancer;Stage IVB Pharyngeal Cancer;Stage IVC Pharyngeal Cancer;Thyroid Gland Neoplasm | Biological: Bevacizumab;Biological: Cetuximab;Other: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: Temsirolimus;Drug: Valproic Acid | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | Recruiting | N/A | N/A | All | 216 | Phase 1 | United States |
| 17 | JPRN-JMA-IIA00037 | 01/10/2011 | 2 April 2019 | MLLTS trial | Multicenter Lymphangioleiomyomatosis Long Term Sirolimus Trial | lymphangioleiomyomatosis | Intervention type:DRUG. Intervention1:sirolimus, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:LAM patients will be medicated with 2mg of sirolimus every day for 2 years.. | Koh Nakata, MD, Ph.D | Ryushi Tazawa | Not Recruiting | >=18 YEARS | No Limit | Female | 50 | Phase 2 | Japan |
| 18 | NCT01353209 | May 2011 | 7 September 2015 | Trial of Aromatase Inhibition in Lymphangioleiomyomatosis | A TRIAL OF LETROZOLE IN PULMONARY LYMPHANGIOLEIOMYOMATOSIS | Lymphangioleiomyomatosis | Drug: Letrozole;Drug: Placebo | University of Cincinnati | Department of Defense | Not recruiting | 18 Years | N/A | Female | 17 | Phase 2 | United States |
| 19 | EUCTR2010-019825-32-IT | 28/07/2010 | 18 March 2013 | An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis. - ND | An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis. - ND | Lymphangioleiomyomatosis MedDRA version: 12.1 Level: LLT Classification code 10049459 Term: Lymphangioleiomyomatosis | Pharmaceutical Form: Tablet INN or Proposed INN: Everolimus Current Sponsor code: RAD001 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical Form: Tablet INN or Proposed INN: Everolimus Current Sponsor code: RAD001 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical Form: Tablet INN or Proposed INN: Everolimus Current Sponsor code: RAD001 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | NOVARTIS FARMA | Not Recruiting | Female: yes Male: no | 24 | France;Italy | ||||
| 20 | NCT01059318 | December 2009 | 19 February 2015 | A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis | An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis | Lymphangioleiomyomatosis | Drug: Everolimus | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | Female | 22 | Phase 2 | United States;France;Germany;Italy | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT00989742 | July 2009 | 14 December 2015 | Doxycycline In Lymphangioleiomyomatosis (LAM) | A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis. | Lymphangioleiomyomatosis;Tuberous Sclerosis | Drug: Doxycycline;Drug: Placebo | University of Nottingham | Not recruiting | 18 Years | N/A | Female | 24 | Phase 4 | United Kingdom | |
| 22 | NCT00790400 | April 2009 | 16 December 2017 | Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC);Lymphangioleiomyomatosis (LAM) | Drug: Everolimus (RAD001);Drug: Everolimus Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 118 | Phase 3 | United States;Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom | |
| 23 | EUCTR2007-003745-32-GB | 12/12/2008 | 30 June 2014 | A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. - Doxycycline in LAM | A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. - Doxycycline in LAM | Lymphangioleiomyomatosis MedDRA version: 9.1 Level: LLT Classification code 10049459 Term: Lymphangioleiomyomatosis MedDRA version: 9.1 Level: PT Classification code 10049459 Term: Lymphangioleiomyomatosis | Trade Name: Doxycycline 100 mg Capsules Pharmaceutical Form: Capsule* INN or Proposed INN: doxycycline Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | University of Nottingham | Not Recruiting | Female: yes Male: no | United Kingdom | |||||
| 24 | NCT00792766 | December 2008 | 19 February 2015 | Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) | Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis | Tuberous Sclerosis;Angiolipoma | Drug: everolimus (RAD001) | Children's Hospital Medical Center, Cincinnati | Novartis | Not recruiting | 18 Years | 65 Years | Both | 20 | Phase 1/Phase 2 | United States |
| 25 | JPRN-JMA-IIA00011 | 08/05/2008 | 2 April 2019 | Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial (The MILES Trial) | Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial (The MILES Trial) | Lymphangioleiomyomatosis (LAM) | Intervention type:DRUG. Intervention1:Sirolimus, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:12 months on, 12 months off. Control intervention1:Placebo, Dose form:TABLET, Route of administration:ORAL, Intended dose regimen:12 months on, 12 months off. | Frank McCormack, M.D., University of Cincinnati Medical Center Director, Division of Pulmonary and Critical Care Medicine | a. Alan F. Barker, M.D. - Oregon Health & Sciences University b. Kevin Brown, M.D., - National Jewish Medical & Research Center c. Edwin K. Silverman, M.D., Ph.D. - Harvard/Brigham & Women's Hospital d. James M. Stocks, M.D. - University of Texas Health Center e. James K. Stoller, M.D. - Cleveland Clinic Foundation f. Charlie Strange, M.D. - Medical University of South Carolina g. Bruce Trapnell, M.D.-Cincinnati Children's Medical Center h. Mark Brantly, M.D.-University of Florida, Gainesville i. Yosdhikazu Inoue, M.D., National Hospital Organization (NHO) Kinki-Chuo Chest Medical Center j. Koh Nakata, M.D., Ph.D., Bioscience Medical Research Center, Niigata University Medical and Dental Hospital k. Joel Moss, M.D., Ph.D-National Institutes of Health | Not Recruiting | >=18 YEARS | Female | 120 | Phase 3 | Japan, United States, Canada | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT00414648 | December 2006 | 19 February 2015 | Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM) | Lymphangioleiomyomatosis Efficacy and Safety Trial | Lymphangioleiomyomatosis | Drug: Sirolimus;Drug: Placebo sirolimus | Office of Rare Diseases (ORD) | FDA Office of Orphan Products Development | Not recruiting | 18 Years | N/A | Female | 120 | Phase 3 | United States;Canada;Japan |
| 27 | NCT00490789 | October 2005 | 19 February 2015 | Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM | A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis | Tuberous Sclerosis;Lymphangioleiomyomatosis | Drug: sirolimus | Cardiff University | University of Nottingham;St Georges Hospital Medical School;Royal Sussex County Hospital;The Tuberous Sclerosis Association;Wyeth is now a wholly owned subsidiary of Pfizer | Not recruiting | 18 Years | 65 Years | Both | 14 | Phase 2 | United Kingdom |
| 28 | NCT00457964 | August 2005 | 19 February 2015 | RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM | RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis | Tuberous Sclerosis;Lymphangioleiomyomatosis | Drug: RAD001 | Children's Hospital Medical Center, Cincinnati | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | Both | 36 | Phase 1/Phase 2 | United States |
| 29 | NCT00457808 | December 2002 | 19 February 2015 | Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM | Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis | Tuberous Sclerosis;Lymphangioleiomyomatosis | Drug: Rapamycin, sirolimus | Children's Hospital Medical Center, Cincinnati | The LAM Foundation;Tuberous Sclerosis Alliance | Not recruiting | 18 Years | 65 Years | Both | 25 | Phase 2 | United States |
| 30 | NCT00005906 | June 2000 | 19 October 2017 | Treatment With Octreotide in Patients With Lymphangioleiomyomatosis | Treatment With Octreotide in Patients With Lymphangioleiomyomatosis | Lymphangioleiomyomatosis;Lymphangiomyomas;Pleural Effusions;Ascites | Drug: Octreotide | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 18 Years | 65 Years | Female | 4 | Phase 2 | United States |